Abstract CT115: Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
Yu Sawada(Yokohama City University), Tetsuya Nakatsura(Unknown), Shoichi Mizuno(Shizuoka Cancer Center), Itaru Endo(Yokohama City University), Toshiaki Yoshikawa(Aichi Cancer Center), Daisuke Nobuoka(Fukuyama City Hospital), Kazuya Ofuji(Chiba Cancer Center), Mari Takahashi(Chiba Cancer Center), Mayuko Yoshimura(Chiba Cancer Center), Nobuhiro Tsuchiya(Yokohama City University)
Cited by 0
Related Papers
Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
|Clinical Cancer Research|2012|304
Clinical practice guidelines for the management of biliary tract cancers 2015: the 2<sup>nd</sup> English edition
|Journal of Hepato-Biliary-Pancreatic Sciences|2015|300
Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English edition
|Journal of Hepato-Biliary-Pancreatic Sciences|2020|235
Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
|OncoImmunology|2016|178
Risk factors for major morbidity after liver resection for hepatocellular carcinoma
|British journal of surgery|2012|104